Sozzi Gabriella, Martelli Maria Paola, Conte Davide, Modena Piergiorgio, Pettirossi Valentina, Pileri Stefano A, Falini Brunangelo
Istituto Nazionale Tumori, Milan, Italy.
Haematologica. 2009 Sep;94(9):1307-11. doi: 10.3324/haematol.2009.008045.
Rearrangements involving the ALK gene define two distinct entities in the new 2008 WHO classification of lymphoid neoplasms, i.e. ALK+ anaplastic large cell lymphoma and a rare subset of ALK+ diffuse large B-cell lymphoma. Recently, rearrangements involving ALK and the echinoderm microtubule associated protein-like 4 (EML4) gene were described as a specific genetic alteration in about 6% of non-small cell lung cancer (NSCLC). We investigated the expression of EML4-ALK mRNA and protein in 51 reactive and 58 neoplastic lymphoid tissues. EML4-ALK transcripts were detected in 3/51 (5.9%) of reactive lymphoid tissues and 12/58 (20.7%) of lymphomas of different categories, including follicular lymphoma, diffuse large B-cell lymphoma and Hodgkin's disease. Notably, none of these cases expressed the EML4-ALK fusion protein at Western blotting samples and immunohistochemistry. These results indicate that EML4-ALK rearrangements are not specific of NSCLC and raise yet unsolved questions about their role in promoting human neoplasms.
在2008年世界卫生组织淋巴样肿瘤新分类中,涉及ALK基因的重排定义了两个不同的实体,即ALK阳性间变性大细胞淋巴瘤和ALK阳性弥漫性大B细胞淋巴瘤的一个罕见亚组。最近,涉及ALK和棘皮动物微管相关蛋白样4(EML4)基因的重排被描述为约6%的非小细胞肺癌(NSCLC)中的一种特异性基因改变。我们研究了51例反应性和58例肿瘤性淋巴组织中EML4-ALK mRNA和蛋白的表达。在3/51(5.9%)的反应性淋巴组织和12/58(20.7%)的不同类型淋巴瘤(包括滤泡性淋巴瘤、弥漫性大B细胞淋巴瘤和霍奇金病)中检测到EML4-ALK转录本。值得注意的是,在蛋白质印迹样本和免疫组织化学检测中,这些病例均未表达EML4-ALK融合蛋白。这些结果表明,EML4-ALK重排并非NSCLC所特有,并引发了关于其在促进人类肿瘤发生中作用的尚未解决的问题。